Supplementary Figure S3 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas

Authors:
  • SLSimonetta M. Leto
    Simonetta M. Leto
  • FSFrancesco Sassi
    Francesco Sassi
  • ICIrene Catalano
    Irene Catalano
  • VTValter Torri
    Valter Torri
  • GMGiorgia Migliardi
    Giorgia Migliardi
  • EZEugenia R. Zanella
    Eugenia R. Zanella
  • MTMark Throsby
    Mark Throsby
  • ABAndrea Bertotti
    Andrea Bertotti
  • LTLivio Trusolino
    Livio Trusolino

Abstract
Signaling consequences of treatment with trastuzumab, lapatinib and their combination in HER2-positive colorectal and gastric cancer cells: Duplicate bots for HER receptors.